TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9060078

Group type: EXPERIMENTAL
Intervention: Ipsilateral adrenalectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ipsilateral adrenalectomy (Control)
Number of subjects: 40
Study: 8360732

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 3521798

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 100
Study: 29066616

Group type: EXPERIMENTAL
Intervention: Precommitment intervention with decision supports and reminders for Choosing Wisely recommendations
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no precommitment intervention)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3-month postintervention follow-up
Number of subjects: 45
Study: 27640187

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including smoke-free school grounds, smoke-free curriculum, and parental involvement.
Number of subjects: 4161

Group type: COMPARATOR
Intervention: Control schools (no specific intervention details provided).
Number of subjects: 4161
Study: 23968972

Group type: EXPERIMENTAL
Intervention: Soft-soled shoe (Shore A25)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Medium-soled shoe (Shore A40)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hard-soled shoe (Shore A58)
Number of subjects: 35

Group type: COMPARATOR
Intervention: All shoe conditions
Number of subjects: 35
Study: 23782995

Group type: EXPERIMENTAL
Intervention: Early postpartum home biofeedback physiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pelvic floor exercises (PFEs)
Number of subjects: 120
Study: 20839572

Group type: EXPERIMENTAL
Intervention: Placentrex injection combined with antimicrobial therapy (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antimicrobial therapy alone (Group II)
Number of subjects: 100
Study: 18823261

Group type: EXPERIMENTAL
Intervention: Qigong practice
Number of subjects: 37

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 37
Study: 16473983

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 30
Study: 12072632

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bipolar scissors hemorrhoidectomy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy (scissors excision‐ligation technique)
Number of subjects: 86
Study: 10604829

Group type: EXPERIMENTAL
Intervention: Neoral capsules, 5 mg/kg twice a day for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sandimmune (SIM) capsules, 5 mg/kg twice a day for 12 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Neoral capsules
Number of subjects: 96
Study: 8942775

Group type: EXPERIMENTAL
Intervention: Faecal-occult-blood (FOB) screening
Number of subjects: 150251

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 150251
Study: 1663301

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (aluminium hydroxide)
Number of subjects: 0
Study: 6752738

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.0, 0.125, 0.25, and 0.5 mg given intravenously over 30 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 10
Study: 31918946

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent (RES)
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2221
Study: 29180278

Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg
Number of subjects: 104
Study: 26694499

Group type: EXPERIMENTAL
Intervention: Training-ESA (TE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary-ESA (SE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Training-Placebo (TP)
Number of subjects: 36
Study: 24732230

Group type: EXPERIMENTAL
Intervention: Accelerated Seldinger technique (AST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Seldinger technique (MST)
Number of subjects: 0
Study: 22210925

Group type: EXPERIMENTAL
Intervention: Orlistat (lipase inhibitor)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No Orlistat
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CD36 genotype (AA, AG, GG)
Number of subjects: 21
Study: 21351255

Group type: EXPERIMENTAL
Intervention: Full-length adiponectin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: AdipoR1 and AdipoR2 expression levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: AdipoR1 and AdipoR2 immunostaining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microarray analysis
Number of subjects: 0
Study: 18036907

Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (titrated intravenous insulin infusion)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard high-dose systemic insulin infusion at 5 mU/kg/min
Number of subjects: 44
Study: 16286438

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 12128237

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 50
Study: 9823789

Group type: EXPERIMENTAL
Intervention: Thrombolytic regimens (bolus thrombolysis, glycoprotein IIb/IIIa inhibition, low‐molecular‐weight heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering with statin drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 8043977

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 11
Study: 3377212

Group type: EXPERIMENTAL
Intervention: 0.42% NaHCO3 solution added to bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline added to bupivacaine
Number of subjects: 40
Study: 31573392

Group type: EXPERIMENTAL
Intervention: Glissonean pedicle transection with hepatic vein exclusion (Glisson group, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pringle maneuver with intermittent clamping (Pringle group, n = 25)
Number of subjects: 50
Study: 29174310

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg once daily for 24 months)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (vinorelbine 25 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for four cycles)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 222

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin
Number of subjects: 222
Study: 27464735

Group type: EXPERIMENTAL
Intervention: Coping with Accident Reactions (CARE) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 25437581

Group type: EXPERIMENTAL
Intervention: 1-port LC using SILS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2-port LC using a laparoscope with a working channel
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 3-port LC using standard ports
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 3
Study: 22878176

Group type: EXPERIMENTAL
Intervention: L5-S1 HVLA spinal manipulation (SM) procedure
Number of subjects: 66

Group type: COMPARATOR
Intervention: L5-S1 joint pre-loading procedure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 66
Study: 20151469

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18501565

Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-patient control group
Number of subjects: 42
Study: 16392989

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Stress management and wellness (SMW) training
Number of subjects: 92
Study: 16281510

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/d) and acetyl-L-carnitine (1 g/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vitamin E (100 mg) plus Vitamin C (100 mg)
Number of subjects: 150
Study: 11057854

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) concentrates
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 9121974

Group type: COMPARATOR
Intervention: Transvenous lead alone
Number of subjects: 267

Group type: COMPARATOR
Intervention: Transvenous lead linked to a patch electrode
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Transvenous lead linked to the investigational array electrode
Number of subjects: 267
Study: 8489061

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 0 cmH2O
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 5 cmH2O
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cmH2O
Number of subjects: 6
Study: 3552909

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 1-2 g
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 27
Study: 2680430

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 360 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31720916

Group type: EXPERIMENTAL
Intervention: Culturable microbial diversity from salterns
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Molecular screening for biosynthetic genes
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sequencing of amplicons
Number of subjects: 190
Study: 31027963

Group type: EXPERIMENTAL
Intervention: Noninvasive (information, self‐exercise, occlusal splints)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Minimally invasive (information, arthrocentesis with lavage, manipulation, postoperative self‐exercise)
Number of subjects: 24
Study: 28906574

Group type: EXPERIMENTAL
Intervention: Combination of picosecond laser (1 064 and 595 nm) and 2% hydroquinone (HQ) cream for 7 weeks and 5 weeks of laser treatment (weekly).
Number of subjects: 78

Group type: COMPARATOR
Intervention: 2% hydroquinone (HQ) cream alone for 7 weeks.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Picosecond laser treatment side at week 7.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control side (2% HQ alone) at week 7.
Number of subjects: 78
Study: 25920470

Group type: EXPERIMENTAL
Intervention: Motor training involving the less-affected side (MTLA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Neurophysiological-based conventional therapy
Number of subjects: 35
Study: 23439301

Group type: EXPERIMENTAL
Intervention: Pegylated interferon with ribavirin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pegylated interferon without ribavirin
Number of subjects: 114
Study: 21742943

Group type: EXPERIMENTAL
Intervention: Algae‐derived DHA (12 g·ewe(‐1)·d(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no algae‐derived DHA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Algae‐derived DHA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 20003384

Group type: EXPERIMENTAL
Intervention: Brief sex counselling
Number of subjects: 450

Group type: COMPARATOR
Intervention: Intensive sexological treatment
Number of subjects: 450

Group type: COMPARATOR
Intervention: Delayed treatment (waiting list)
Number of subjects: 450
Study: 17100679

Group type: EXPERIMENTAL
Intervention: AV sequential pacing mode
Number of subjects: 72

Group type: COMPARATOR
Intervention: VVI pacing mode
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 72
Study: 16097633

Group type: EXPERIMENTAL
Intervention: Acetazolamide stress
Number of subjects: 0
Study: 11262572

Group type: COMPARATOR
Intervention: Oxygen therapy (O2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Noninvasive bilevel positive pressure ventilation
Number of subjects: 26
Study: 9329422

Group type: EXPERIMENTAL
Intervention: Topical iodine-containing antiseptics (n = 73)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chlorhexidine-containing antiseptics (n = 55)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Topical iodine-containing antiseptics (n = 24)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chlorhexidine (n = 22)
Number of subjects: 128
Study: 8204876

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 beta (rhIL‐1 beta) at 0.01, 0.02, 0.05 microgram/kg administered by intravenous infusion once a day for 5 doses.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 beta (rhIL‐1 beta)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Historical control (no rhIL‐1 beta)
Number of subjects: 17
Study: 3295018

Group type: EXPERIMENTAL
Intervention: Portacaval shunt (PCS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stapler transection (ST)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 70
Study: 30350337

Group type: EXPERIMENTAL
Intervention: Nocturnal home blood pressure measurement adapted to the chosen bedtime of participants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed time points (2:00, 3:00, and 4:00 am) for nocturnal home blood pressure measurement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bedtime-based measurement phase
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed-time measurement phase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nocturnal home BP measurement adapted to the chosen bedtime
Number of subjects: 48
Study: 28858553

Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (LB) 133 mg/10 mL
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25908603

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab 5 mg/kg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab 10 mg/kg
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard treatment)
Number of subjects: 387
Study: 23681683

Group type: EXPERIMENTAL
Intervention: Integrated care intervention carried out by LPNs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 21167586

Group type: EXPERIMENTAL
Intervention: Standard method of calculation using median strength value at each stress rate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Statistical regression method
Number of subjects: 150
Study: 18504478

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INS)
Number of subjects: 0
Study: 17143153

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 0
Study: 14570788

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nasopharyngeal intubation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nasopharyngeal intubation plus direct laryngoscopy
Number of subjects: 75
Study: 11144071

Group type: EXPERIMENTAL
Intervention: Mitchell's modified method using Dallos polyester fiber prosthesis
Number of subjects: 53
Study: 8860730

Group type: EXPERIMENTAL
Intervention: 50 Hz, 100 mu T magnetic field exposure for 9 min
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham exposure for 9 min
Number of subjects: 100
Study: 1844696

Group type: EXPERIMENTAL
Intervention: Proposed method using individual subject ratios for assessing bioequivalence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logarithmic transformation
Number of subjects: 0
Study: 6364297

Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort) 200 micrograms b.i.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (Becotide Nasal) 200 micrograms b.i.d.
Number of subjects: 52
Study: 31753900

Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting (BCC) as add-on to usual dietary care
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual dietary care
Number of subjects: 226
Study: 29378476

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study: 27756405

Group type: EXPERIMENTAL
Intervention: Active binocular treatment (videogame-based) for 6 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Active binocular treatment (videogame-based)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 108
Study: 25480528

Group type: EXPERIMENTAL
Intervention: Adjustable guiding device and DICOM image-reading software assistance for ventriculostomy catheter placement.
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard freehand ventriculostomy using anatomical landmarks.
Number of subjects: 236
Study: 22705318

Group type: EXPERIMENTAL
Intervention: OptrexActiMist (AM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: DryEyesMist (DEM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: TearMist (TM)
Number of subjects: 80
Study: 20502361

Group type: EXPERIMENTAL
Intervention: vinorelbine/paclitaxel plus carboplatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study: 18318948

Group type: EXPERIMENTAL
Intervention: 10% silver vitellinate
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 76
Study: 15830290

Group type: EXPERIMENTAL
Intervention: High cholesterol intake (highest tertile)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High vitamin C intake (highest tertile)
Number of subjects: 109
Study: 11833019

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus with mechanical noise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vibrotactile stimulus without mechanical noise
Number of subjects: 25
Study: 9935018

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 7753966

Group type: EXPERIMENTAL
Intervention: Ipsapirone 5 mg administered by mouth three times daily for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ipsapirone 5 mg
Number of subjects: 18
Study: 2113488

Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: hMG with leuprolide acetate (LA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All treatment cycles pooled
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with LA
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Serum concentrations of luteal phase steroids
Number of subjects: 59
Study: 365537

Group type: EXPERIMENTAL
Intervention: S-carboxy-methyl-cysteine (S.C.M.C.) 3 g/24h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30540587

Group type: EXPERIMENTAL
Intervention: Intraoral FSCS simulator training (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Skull model training (Group B)
Number of subjects: 20
Study: 28052910

Group type: EXPERIMENTAL
Intervention: Acupuncture plus PC6 wristband
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PC6 wristband alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: No acupuncture or wristband (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 25299534

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (3 MHz, 1 W/cm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (3 MHz, 1 W/cm, 1:1 ratio)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 60
Study: 23439898

Group type: EXPERIMENTAL
Intervention: Computer-generated reminders
Number of subjects: 1611

Group type: COMPARATOR
Intervention: No computer-generated reminders (Control)
Number of subjects: 1611
Study: 20664387

Group type: EXPERIMENTAL
Intervention: Intensive 6‐month behavioral weight loss program followed by a 12‐month weight maintenance program (n=226)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Structured education program (control; n=112)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Weight loss of 5% to less than 10% of body weight
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Weight loss of 10% or more of body weight
Number of subjects: 338
Study: 18710905

Group type: EXPERIMENTAL
Intervention: Nocturnal non-invasive positive pressure ventilation (NIPPV) + rehabilitation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 72
Study: 16882628

Group type: EXPERIMENTAL
Intervention: Sensory-level high-volt pulsed electrical current (HVPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo condition (no electrical current)
Number of subjects: 20
Study: 14640857

Group type: EXPERIMENTAL
Intervention: Self-directed exercise activity
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonexercise participants
Number of subjects: 28
Study: 11027033

Group type: EXPERIMENTAL
Intervention: Obesity in males (15.7%)
Number of subjects: 8957

Group type: EXPERIMENTAL
Intervention: Underweight prevalence
Number of subjects: 8957

Group type: EXPERIMENTAL
Intervention: Short stature prevalence
Number of subjects: 8957
Study: 1536810

Group type: EXPERIMENTAL
Intervention: Included patients in the clinical trial
Number of subjects: 180

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-reported patients
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tentative application of exclusion criteria (lower age limit, exclusion of renal failure or low performance status)
Number of subjects: 180